tiprankstipranks
Trending News
More News >
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
Advertisement

BioMarin Pharmaceutical (BMRN) AI Stock Analysis

Compare
2,240 Followers

Top Page

BMRN

BioMarin Pharmaceutical

(NASDAQ:BMRN)

Rating:77Outperform
Price Target:
$66.00
▲(13.27% Upside)
BioMarin Pharmaceutical's strong financial performance and positive earnings call guidance are the most significant factors driving the score. The company's strategic initiatives and pipeline advancements further bolster its outlook. However, neutral technical indicators and valuation metrics suggest a balanced risk-reward profile. The recent board expansion adds a positive governance aspect.
Positive Factors
Financial Performance
BMRN reported higher than expected second quarter total sales of $825M, an 11% QoQ increase.
Revenue Growth
Voxzogo's strong global expansion led to revenue growth, with revenue at $221 million, above estimates and consensus.
Negative Factors
Market Competition
Impending Voxzogo competition is expected by year-end, which could impact its market position.
Patent Issues
The EU patent Board's preliminary decision suggests that a BioMarin patent lacks disclosure needed to differentiate from prior art.

BioMarin Pharmaceutical (BMRN) vs. SPDR S&P 500 ETF (SPY)

BioMarin Pharmaceutical Business Overview & Revenue Model

Company DescriptionBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
How the Company Makes MoneyBioMarin generates revenue primarily through the sale of its pharmaceutical products, which are targeted at rare diseases. Key revenue streams include the sale of its approved therapies, such as Vimizim (elosulfase alfa), Brineura (cerliponase alfa), and Kuvan (sapropterin dihydrochloride). Additionally, the company engages in partnerships and collaborations with other pharmaceutical and biotechnology firms to enhance its research capabilities and expand its market reach. These partnerships may involve co-development agreements, licensing fees, and milestone payments that contribute to BioMarin's earnings. The company's focus on rare diseases often allows it to command higher prices for its specialized treatments, further bolstering its revenue.

BioMarin Pharmaceutical Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Breaks down revenue across different business units, highlighting which products or services drive the most sales and indicating areas of growth or potential risk.
Chart InsightsBioMarin's Voxzogo segment is experiencing robust growth, with revenues rising significantly due to global expansion efforts. Despite a slight adjustment in full-year guidance, the segment's upward trajectory remains strong, contributing to the company's overall 16% revenue growth. Enzyme therapies also show solid performance, bolstered by strategic acquisitions like Inozyme. However, increased operating expenses and strategic investments may dampen earnings in the latter half of 2025, suggesting a need for careful financial management to sustain profitability.
Data provided by:Main Street Data

BioMarin Pharmaceutical Earnings Call Summary

Earnings Call Date:Aug 04, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 22, 2025
Earnings Call Sentiment Positive
BioMarin Pharmaceuticals reported strong revenue growth, successful acquisition of Inozyme, and significant progress in their pipeline, which were slightly offset by increased operating expenses and adjusted revenue guidance for VOXZOGO.
Q2-2025 Updates
Positive Updates
Strong Revenue Growth
Total revenues grew 16% in Q2 2025 and 15% in the first half of 2025 compared to the same period in 2024, driven by global demand and new patient starts.
VOXZOGO Revenue Increase
VOXZOGO revenue increased 20% year-over-year to $221 million, with expectations for second half revenue to be higher than the first half.
Inozyme Acquisition
Successfully completed the acquisition of Inozyme on July 1, broadening the enzyme therapies portfolio with BMN 401.
Pipeline Progress
BMN 333 achieved target profile for achondroplasia, with plans to advance to a Phase II/III study. BMN 401 pivotal data expected in 2026.
Profitability Expansion
Non-GAAP diluted earnings per share increased more than 3x the rate of revenue growth, reflecting strong operating margin performance.
Negative Updates
Increased Operating Expenses
Non-GAAP SG&A increased year-over-year due to investments in enterprise resource planning system and strategic initiatives, with expectations for higher expenses in the second half.
Potential Lower Profitability in Q3
Higher operating expenses anticipated in the second half of 2025, leading to expected lower profitability in Q3 compared to Q4.
VOXZOGO Revenue Guidance Adjustment
Brought down the top end of VOXZOGO revenue guidance range from $950 million to $935 million due to shifting of large orders and better forecasting.
Company Guidance
During BioMarin Pharmaceuticals' second-quarter 2025 call, the company provided updated guidance reflecting robust financial and operational performance. The guidance highlighted an increase in full-year 2025 total revenue expectations, now projected between $3.125 billion, supported by 16% revenue growth in Q2. Key drivers included a 20% year-over-year surge in VOXZOGO revenue, totaling $221 million, and a 15% increase in enzyme therapies revenue, reaching $555 million. The company also raised its non-GAAP operating margin guidance to between 33% and 34%, and non-GAAP earnings per share are now anticipated to range from $4.40 to $4.55. This upward revision is attributed to strong commercial execution, particularly VOXZOGO's global expansion and strategic initiatives within its Skeletal Conditions business unit. Additionally, BioMarin reiterated its commitment to advancing its pipeline, including BMN 333 and BMN 401, while emphasizing continued strategic business development to enhance its growth strategy.

BioMarin Pharmaceutical Financial Statement Overview

Summary
BioMarin Pharmaceutical demonstrates solid financial health with strong revenue growth, improved profitability, and effective cash flow management. The balance sheet remains robust with low leverage, supporting long-term stability. While operational margins show slight pressure, the company's financial trajectory is positive, positioning it well for future growth.
Income Statement
85
Very Positive
BioMarin Pharmaceutical has shown a strong revenue growth trajectory with a 3.97% increase in TTM, supported by a robust gross profit margin of 79.50%. The net profit margin has improved significantly to 21.52% in TTM, indicating enhanced profitability. However, the EBIT margin slightly decreased to 17.84%, suggesting some operational cost pressures.
Balance Sheet
78
Positive
The company's balance sheet is stable with a low debt-to-equity ratio of 0.10, reflecting conservative leverage. Return on equity has improved to 11.48% in TTM, showcasing effective utilization of equity. The equity ratio stands at 80.82%, indicating a strong equity position relative to total assets.
Cash Flow
82
Very Positive
BioMarin's cash flow performance is commendable with an 11.49% growth in free cash flow in TTM. The operating cash flow to net income ratio of 1.12 indicates efficient cash generation relative to net income. The free cash flow to net income ratio of 0.90 further underscores strong cash flow management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.06B2.85B2.42B2.10B1.85B1.86B
Gross Profit2.44B2.27B1.89B1.59B1.38B1.34B
EBITDA895.24M650.86M310.28M267.51M48.03M13.41M
Net Income657.24M426.86M167.65M141.56M-64.08M854.03M
Balance Sheet
Total Assets7.46B6.99B6.84B6.38B6.00B5.85B
Cash, Cash Equivalents and Short-Term Investments1.43B1.14B1.07B1.29B1.01B1.07B
Total Debt603.87M602.71M1.10B1.09B1.09B1.09B
Total Liabilities1.43B1.33B1.89B1.77B1.74B1.74B
Stockholders Equity6.03B5.66B4.95B4.60B4.27B4.11B
Cash Flow
Free Cash Flow691.43M475.42M51.65M44.36M185.31M-52.15M
Operating Cash Flow766.77M572.84M159.26M175.90M304.54M85.36M
Investing Cash Flow19.42M136.49M-111.24M-20.03M-366.31M-53.62M
Financing Cash Flow-539.65M-526.45M-18.73M-18.65M-48.00K181.12M

BioMarin Pharmaceutical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price58.27
Price Trends
50DMA
57.73
Positive
100DMA
58.32
Negative
200DMA
62.40
Negative
Market Momentum
MACD
-0.03
Positive
RSI
50.79
Neutral
STOCH
56.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRN, the sentiment is Positive. The current price of 58.27 is below the 20-day moving average (MA) of 58.36, above the 50-day MA of 57.73, and below the 200-day MA of 62.40, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 50.79 is Neutral, neither overbought nor oversold. The STOCH value of 56.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BMRN.

BioMarin Pharmaceutical Risk Analysis

BioMarin Pharmaceutical disclosed 47 risk factors in its most recent earnings report. BioMarin Pharmaceutical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

BioMarin Pharmaceutical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
$15.30B12.3226.08%23.25%64.46%
80
Outperform
$16.52B19.2324.30%18.87%1088.27%
78
Outperform
$13.78B11.9019.30%17.62%19.89%
77
Outperform
$11.19B17.2611.62%17.38%153.58%
75
Outperform
$10.07B17.9529.00%10.73%81.66%
61
Neutral
$11.76B357.68%55.77%46.81%
51
Neutral
$7.86B-0.26-41.41%2.22%22.87%-2.01%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BMRN
BioMarin Pharmaceutical
58.27
-33.33
-36.39%
EXEL
Exelixis
37.42
11.59
44.87%
INCY
Incyte
84.61
18.30
27.60%
UTHR
United Therapeutics
304.76
-47.64
-13.52%
ASND
Ascendis Pharma
194.27
59.59
44.25%
GMAB
Genmab
24.87
-2.54
-9.27%

BioMarin Pharmaceutical Corporate Events

Executive/Board Changes
BioMarin Announces Resignation of Chief Accounting Officer
Neutral
Aug 11, 2025

On August 5, 2025, BioMarin Pharmaceutical announced the resignation of Erin Burkhart, their Group Vice President and Chief Accounting Officer, effective September 2, 2025. The company will search for her successor, and in the interim, Brian Mueller, the Executive Vice President and Chief Financial Officer, will assume her responsibilities without additional compensation.

Executive/Board ChangesBusiness Operations and Strategy
BioMarin Expands Board with New Director Appointment
Positive
Aug 1, 2025

On July 30, 2025, BioMarin Pharmaceutical‘s Board of Directors expanded from ten to eleven members, appointing Ian T. Clark effective August 1, 2025. Mr. Clark joins the Audit and Science and Technology Committees, receiving standard director fees and a $400,000 restricted stock unit grant. This strategic move aims to strengthen BioMarin’s governance and oversight, potentially enhancing its industry positioning and stakeholder confidence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 30, 2025